Skip to main content

Table 3 Patient characteristics based on the clinical efficacies

From: Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study

at baseline

GETE ≥ good (n = 14)

GETE ≤ moderate (n = 10)

p value

ΔFEV1 ≥ 200 ml (n = 8)

ΔFEV1 < 200 ml (n = 16)

p value

sex (M/F), n

4 / 10

5 / 5

0.40

5 / 3

4 / 12

0.099

age (years)

57.6 (12.1)

57.2 (15.7)

0.79

51.6 (15.8)

60.4 (11.5)

0.15

—MEPO (−) (n = 13)

56.9 (12.6) (n = 8)

56.4 (21.8) (n = 5)

0.71

52.8 (19.4) (n = 5)

59.1 (14.0) (n = 8)

0.51

—MEPO (+) (n = 11)

58.7 (12.6) (n = 6)

58.0 (9.0) (n = 5)

0.85

49.7 (10.2) (n = 3)

61.6 (9.2) (n = 8)

0.098

BMI (kg/m2)

22.0 (4.2)

25.3 (5.1)

0.09

24.7 (5.5)

22.7 (4.4)

0.46

—MEPO (−) (n = 13)

22.6 (5.0) (n = 8)

27.7 (3.8) (n = 5)

0.079

26.2 (5.0) (n = 5)

23.5 (5.3) (n = 8)

0.38

—MEPO (+) (n = 11)

21.2 (2.9) (n = 6)

22.8 (5.4) (n = 5)

0.58

22.1 (6.3) (n = 3)

21.8 (3.5) (n = 8)

0.84

bEOS (/μl)

306 (216)

271 (426)

0.20

407 (424)

234 (234)

0.27

—MEPO (−) (n = 13)

437 (183) (n = 8)

492 (531) (n = 5)

0.66

565 (472) (n = 5)

391 (236) (n = 8)

0.66

—MEPO (+) (n = 11)

132 (104) (n = 6)

50 (35) (n = 5)

0.20

143 (127) (n = 3)

77 (71) (n = 8)

0.31

bBASO (/μl)

33 (29)

38 (27)

0.46

49 (40)

28 (16)

0.34

—MEPO (−) (n = 13)

28 (18) (n = 9)

46 (35) (n = 5)

0.38

41 (37) (n = 5)

31 (19) (n = 8)

0.77

—MEPO (+) (n = 11)

40 (40) (n = 6)

29 (13) (n = 5)

0.86

61 (51) (n = 3)

26 (13) (n = 8)

0.31

FeNO (ppb)

70 (42)

41 (26)

0.08

70 (39)

53 (38)

0.26

—MEPO (−) (n = 13)

74 (49) (n = 8)

47 (30) (n = 5)

0.27

66 (42) (n = 5)

63 (48) (n = 8)

0.71

—MEPO (+) (n = 10)a

64 (33) (n = 6)

33 (22) (n = 4)a

0.11

75 (43) (n = 3)

42 (23) (n = 7)a

0.25

%FVC (%)

99.1 (17.6)

88.9 (7.2)

0.04†

83.8 (9.9)

100.4 (14.0)

0.005†

—MEPO (−) (n = 13)

101.0 (19.6) (n = 8)

88.3 (5.9) (n = 5)

0.04†

84.6 (12.8) (n = 5)

103.3 (15.1) (n = 8)

0.04

—MEPO (+) (n = 11)

96.7 (15.9) (n = 6)

89.4 (9.0) (n = 5)

0.47

82.3 (3.2) (n = 3)

97.5 (13.1) (n = 8)

0.07

%FEV1 (%)

83.2 (22.8)

71.7 (19.9)

0.18

64.0 (12.9)

85.6 (22.2)

0.024†

—MEPO (−) (n = 13)

86.2 (20.6) (n = 8)

69.5 (28.6) (n = 5)

0.38

60.5 (14.3) (n = 5)

91.8 (25.2) (n = 8)

0.028†

—MEPO (+) (n = 11)

79.1 (13.1) (n = 6)

74.0 (21.3) (n = 5)

0.47

69.7 (9.5) (n = 3)

79.4 (18.4) (n = 8)

0.41

comorbidities

 —with AERD, n (%)

2 (14)

5 (50)

0.085

3 (38)

4 (25)

0.65

 —with ECRS, n (%)

12 (86)

8 (80)

> 0.99

7 (88)

13 (81)

> 0.99

  1. Data at baseline are presented as mean (standard deviation), unless otherwise stated
  2. P value was analyzed using Fisher’s exact test or Mann-Whitney U test
  3. Abbreviations: GETE global evaluation of treatment effectiveness, ΔFEV1 change from baseline to the last follow-up in the forced expiratory volume in 1 s, MEPO previous mepolizumab treatment, BMI body mass index, bEOS peripheral blood eosinophil count at baseline, bBASO peripheral basophil count at baseline, FeNO fractional exhaled nitric oxide, FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, AERD aspirin-exacerbated respiratory disease, ECRS eosinophilic chronic rhinosinusitis, ppb parts-per-billion
  4. †P values with sufficient power that were re-evaluated by a post-hoc power analysis
  5. adata missing (n = 1)
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us